Frequently Asked Questions (FAQs)
Who is Nouveau BioSciences and what do you do?
Nouveau Biosciences is a biotechnology company pioneering a transformative process for engineering new drug for cancer. Our approach centers around a platform technology that leverages principles in synthetic lethality, genomics and computational biology that can precisely target the specific ‘Achilles heel’ of every cancer. The platform output is captured in a proprietary nanopolymer-based drug delivery system that kills tumors more effectively while minimizing side effects.
What is the science behind your technology?
Our technology is unique because it seamlessly integrates fundamental principles in cancer biology with a practical solution for a disease, a unique drug with its own intellectual property (IP). Our highly engineered polymer nanoparticles (PNPs) are designed to increase drug accumulation in cancer cells by as much as 30-fold, while reducing toxicity.
What stage are your programs in?
We have a clinic-ready lead asset targeting pancreatic cancer, AML, and poor prognostic T-cell malignancies. In addition, have developed a pipeline of novel therapeutics with the potential to be first- or best-in-class treatments across the entire cancer spectrum.
Who leads your company?
Our leadership team brings unprecedented experience in every conceivable aspect of drug discovery and development. We are led by our founder and CEO, Owen A. O’Connor, M.D., Ph.D., a globally-renowned physician- scientist, and supported by a world-class leadership team and advisory boards.
How does your platform create new intellectual property?
Our polymer nanoparticle capability enables us to design new, patentable therapeutics by precisely combining drug molecules in a delivery system to bioconcentrates in the tumor microenvironment. This modular approach allows for rapid development of novel compounds that are difficult to replicate using traditional drug design methods.
How far along are you in commercialization or investment?
We’re currently in the private development stage, operating with capital efficiency while achieving significant scientific milestones. Our work has been recognized by leading institutions—we were proud finalists in the 2024 UVA Galant Challenge.
How can I get in touch with you?
We’d love to hear from you. Please reach out via our contact form on the website or email us directly at info@nouveaubiosciences.com.
What is your privacy policy?
We respect your privacy and are transparent about how we handle your data. Our privacy policy outlines what information we collect, how it’s used, and your rights as a user. You can find the full policy on our website, last updated March 28, 2025.